|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Chondrosarcoma
|
0.190 |
Biomarker
|
disease |
HPO |
|
|
|
|
Somatic mutation
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Hyperparathyroidism, Secondary
|
0.020 |
Biomarker
|
disease |
BEFREE |
19-nor-1,25-Dihydroxyvitamin D(2) (paricalcitol) is a noncalcemic vitamin D analog that is approved by the Food and Drug Administration for the treatment of secondary hyperparathyroidism.
|
12813173 |
2003 |
|
Myeloid Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia.
|
15781666 |
2005 |
|
Parathyroid Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
19-nor-1alpha,25(OH)2D2, an analogue of 1alpha,25(OH)2D3 that was originally developed for the treatment of parathyroid disease, has been shown to be less calcemic than 1alpha,25(OH)2D3 in clinical trials.
|
10741714 |
2000 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Extraskeletal myxoid chondrosarcoma (EMC) is a rare mesenchymal neoplasm with a characteristic translocation usually involving NR4A3 and EWSR1.
|
23588370 |
2013 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Extraskeletal myxoid chondrosarcoma is characterized by the reciprocal chromosomal translocation t(9;22) and the resultant fused gene EWS RNA-binding protein 1 and nuclear receptor subfamily 4, group A, member 3 (EWSR1-NR4A3).
|
24508382 |
2014 |
|
Adult Extraskeletal Myxoid Chondrosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Extraskeletal myxoid chondrosarcoma is characterized by the reciprocal chromosomal translocation t(9;22) and the resultant fused gene EWS RNA-binding protein 1 and nuclear receptor subfamily 4, group A, member 3 (EWSR1-NR4A3).
|
24508382 |
2014 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Extraskeletal myxoid chondrosarcoma (EMC) is a rare soft tissue sarcoma, marked by NR4A3 rearrangement.
|
24703573 |
2014 |
|
Adult Extraskeletal Myxoid Chondrosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Extraskeletal myxoid chondrosarcoma with a t(9;16)(q22;p11.2) resulting in a NR4A3-FUS fusion.
|
25130955 |
2014 |
|
B-Cell Lymphomas
|
0.010 |
Biomarker
|
group |
BEFREE |
B cell lymphoma 2 (Bcl-2) residues essential for Bcl-2's apoptosis-inducing interaction with Nur77/Nor-1 orphan steroid receptors.
|
29414782 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor cell proliferation and apoptosis were assessed via a colony-forming assay and Annexin V/propidium iodide staining.<b>Results and conclusions:</b> Expression profile analysis revealed elevated levels of NR4A3 and KLF11 in A549 lung cancer cells after treatment with HT combined with radiation.
|
31498019 |
2019 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
NOR-1 is normally involved in the balance between cell proliferation and cell death, and is implicated in oncogenesis as part of the EWS/NOR-1 fusion protein found in human extraskeletal myxoid chondrosarcoma (EMC) tumors.
|
12543801 |
2003 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
NOR-1 is normally involved in the balance between cell proliferation and cell death, and is implicated in oncogenesis as part of the EWS/NOR-1 fusion protein found in human extraskeletal myxoid chondrosarcoma (EMC) tumors.
|
12543801 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
NOR-1 is normally involved in the balance between cell proliferation and cell death, and is implicated in oncogenesis as part of the EWS/NOR-1 fusion protein found in human extraskeletal myxoid chondrosarcoma (EMC) tumors.
|
12543801 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
NOR1 is an HSF1- and NRF1-regulated putative tumor suppressor inactivated by promoter hypermethylation in nasopharyngeal carcinoma.
|
21803736 |
2011 |
|
Nasopharyngeal carcinoma
|
0.070 |
PosttranslationalModification
|
disease |
BEFREE |
NOR1 is an HSF1- and NRF1-regulated putative tumor suppressor inactivated by promoter hypermethylation in nasopharyngeal carcinoma.
|
21803736 |
2011 |
|
Malignant myoepithelioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
NR4A3 rearrangement reliably distinguishes between the clinicopathologically overlapping entities myoepithelial carcinoma of soft tissue and cellular extraskeletal myxoid chondrosarcoma.
|
22569967 |
2012 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
NR4A3 rearrangement reliably distinguishes between the clinicopathologically overlapping entities myoepithelial carcinoma of soft tissue and cellular extraskeletal myxoid chondrosarcoma.
|
22569967 |
2012 |
|
Adult Extraskeletal Myxoid Chondrosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
NR4A3 rearrangement reliably distinguishes between the clinicopathologically overlapping entities myoepithelial carcinoma of soft tissue and cellular extraskeletal myxoid chondrosarcoma.
|
22569967 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
NOR1 is a putative tumor suppressor gene.
|
23831407 |
2013 |
|
Monocytosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
NOR1 deficiency in hematopoietic stem cells induced splenomegaly and monocytosis, specifically the abundance of inflammatory Ly6C(+) monocytes.
|
24806827 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
NR4A3 re-expression in GC cell lines sensitized the cells to cisplatin, and inhibited tumor growth in vitro and in vivo, in an animal model.
|
27528092 |
2016 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
NOR1 promotes hepatocellular carcinoma cell proliferation and migration through modulating the Notch signaling pathway.
|
28232113 |
2017 |